Table I.
Patient characteristics and response
| Study number | Gender/Age (y) | Disease | # of prior regimens | Baseline ANC | Dosing schedule | # of cycles completed | Response | Reason for discontinuation |
|---|---|---|---|---|---|---|---|---|
| 01 | M/58 | HCL | 4 | 850 | 1200mg/m2 over 48 h | 4 | SD | CT |
| 02 | M/52 | CLL | 6 | 2430 | 1200mg/m2 over 48 h | 4 | SD | CT |
| 03 | M/64 | MM | 9 | 1540 | 1200mg/m2 over 48 h | 2 | NE | WC |
|
| ||||||||
| 04 | M/66 | HCL | 6 | 1080 | 1500mg/m2 over 48 h | 4 | SD | CT |
| 05 | M/55 | CLL | 5 | 1010 | 1500mg/m2 over 48 h | 4 | PD | CT |
| 06 | M/67 | MCL | 4 | 4440 | 1500mg/m2 over 48 h | 1 | NE | Death |
| 07 | F/65 | CLL | 2 | 1850 | 1500mg/m2 over 48 h | 3 | PD | PD |
|
| ||||||||
| 08 | F/65 | CLL | 4 | 670 | 1800mg/m2 over 48 h | 4 | SD | CT |
| 09 | F/61 | MM | 6 | 620 | 1800mg/m2 over 48 h | 1 | PD | PD |
| 10 | F/65 | CLL | 2 | 650 | 1800mg/m2 over 48 h | 1 | PD | PD |
|
| ||||||||
| 11 | M/60 | MCL | 7 | 1280 | 1800mg over 72 h | 3 | PD | PD |
| 12 | F/65 | CLL | 4 | 4150 | 1800mg over 72 h | 4 | SD | CT |
| 13 | M/52 | CLL | 2 | 4110 | 1800mg over 72 h | 4 | SD | CT |
|
| ||||||||
| 14 | M/58 | CLL | 6 | 1730 | 2100mg over 72 h | 4 | PD | CT |
| 15 | F/61 | CLL | 4 | 1200 | 2100mg over 72 h | 4 | SD | CT |
| 16 | M/57 | CLL | 3 | 670 | 2100mg over 72 h | 4 | PD | CT |
HCL: hairy cell leukemia; CLL: chronic lymphocytic leukemia; MM: multiple myeloma; ANC: absolute neutrophil count in cells/μL; SD: stable disease; NE: not evaluable for response; PD: progression of disease; CT: completed therapy as planned; WC: withdrew consent;